Biotech and Therapeutics
Student Lunch and Learn
Joshua P. Fairbank has spent over two decades on both sides of the table; as an investor and as an entrepreneur. He is the president of Orchard Capital Management where he sits on the investment committees for the small cap value and the alternative asset strategies. In 2004 he co-founded and led the investment team at Orchard Ventures, a biotech VC fund. In addition to Orchard Capital and Orchard Ventures he is the cofounder of several companies. At Akebia (NASDAQ:AKBA) he wrote the original business plan, negotiated the spin-out from Procter & Gamble, and served as a founding director. Akebia is developing an anemia drug that mimics the body’s physiological response to high altitude, it has been tested in thousands of patients and is currently in late stage clinical trials. He runs Nymirum as its cofounder and executive chairman. Nymirum is a computational genetics firm that harnesses AI and big data to work on multiple unsolved diseases including cancers, neurodegenerative diseases, and infectious diseases. Fairbank has negotiated successful drug discovery partnerships with several leading global pharmaceutical companies and worked to obtain significant non-dilutive funding. He is a joint inventor on one of the company’s biophysics patents.
Fairbank will be taking meetings with faculty, scientists, healthcare startups, and students, once per month.